Treating a GAD65 antibody-associated limbic encephalitis with basiliximab: A case study

Frontiers in Neurology

Volumn 6, Issue Aug, 2015, Pages

  Widman, Guido ^a   Golombeck, Kristin ^b   Hautzel, Hubertus ^c   Gross, Catharina C ^b   Quesada, Carlos M ^a   Witt, Juri Alexander ^a   Rota Kops, Elena ^d   Ermert, Johannes ^d   Greschus, Susanne ^a   Surges, Rainer ^a   Helmstaedter, Christoph ^a   Wiendl, Heinz ^b   Melzer, Nico ^b   Elger, Christian E ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

Basiliximab; Cytotoxic T lymphocytes; Epilepsy; GAD65; Limbic encephalitis

Indexed keywords

BASILIXIMAB; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; METHYLPREDNISOLONE;

ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; CD8+ T LYMPHOCYTE; DRUG PULSE THERAPY; EPILEPSY; FLOW CYTOMETRY; HUMAN; IMPULSE CONTROL DISORDER; MALE; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANEOPLASTIC NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 84941001774     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fphar.2015.00167     Document Type: Article

References (23)

1. Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol (2010) 67(4):470-8. doi:10.1002/ana.21917.
2. Bien CG, Schulze-Bonhage A, Deckert M, Urbach H, Helmstaedter C, Grunwald T, et al. Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy. Neurology (2000) 55:1823-8. doi:10.1212/WNL.55.12.1823.
3. Helmstaedter C. EpiTrack. Veränderungssensitives Kognitives Screening zur Qualitäts-und Outcomekontrolle der Medikamentösen Epilepsiebehandlung. Monheim: UCB-Pharma (2012).
4. Helmstaedter C, Lendt M, Lux S. VLMT Verbaler Lern-und Merkfähigkeitstest. Göttingen: Beltz Test GmbH (2001).
5. Helmstaedter C, Pohl C, Hufnagel A, Elger CE. Visual learning deficits in nonresected patients with right temporal lobe epilepsy. Cortex (1991) 27:547-55. doi:10.1016/S0010-9452(13)80004-4.
6. Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci (2015) 1338(1):94-114. doi:10.1111/nyas.12553.
7. Bien CG, Vincent A, Barnett MH, Becker AJ, Blümcke I, Graus F, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain (2012) 135(Pt 5):1622-38. doi:10.1093/brain/aws082.
8. Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet (2013) 381(9884):2167-75. doi:10.1016/S0140-6736(12)62190-4.
9. Sasaki H, Chikaraishi T, Furuhata S, Tsutsumi H, Miyano S, Nakano T, et al. Anaphylactic reaction after initial exposure of Basiliximab: case reports. Transplant Proc (2007) 39(10):3457-9. doi:10.1016/j.transproceed.2007.08.104.
10. Baudouin V, Crusiaux A, Haddad E, Schandene L, Goldman M, Loirat C, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody Basiliximab. Transplantation (2003) 76(3):459-63. doi:10.1097/01.TP.0000073809.65502.8F.
11. Barros VR, Rocha V, Garcia VD, Garcia CD. Anaphylactic shock after retreatment with Basiliximab. Transplant Proc (2003) 35(1):579. doi:10.1016/S0041-1345(02)03406-1.
12. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of Basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet (1997) 350(9086):1193-8. doi:10.1016/S0140-6736(97)09278-7.
13. Lueg G, Gross CC, Lohmann H, Johnen A, Kemmling A, Deppe M, et al. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiol Aging (2015) 36(1):81-9. doi:10.1016/j.neurobiolaging.2014.08.008.
14. Chopra A. Ethyl 8-Fluoro-5-[(11)C]Methyl-6-Oxo-4H-Imidazo[1,5-a][1,4]Benzodiazepine-3-Carboxylate. Molecular Imaging and Contrast Agent Database (MICAD). Bethesda, MD: National Center for Biotechnology Information (US) (2008).
15. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TEJ, Johansen-Berg H, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage (2004) 23(S1):208-19. doi:10.1016/j.neuroimage.2004.07.051.
16. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging (2001) 20(1):45-57. doi:10.1109/42.906424.
17. Patenaude B, Smith SM, Kennedy D, Jenkinson MA. Bayesian model of shape and appearance for subcortical brain. Neuroimage (2011) 56(3):907-22. doi:10.1016/j.neuroimage.2011.02.046.
18. Fouka P, Alexopoulos H, Akrivou S, Trohatou O, Politis PK, Dalakas MC. GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders. J Neuroimmunol (2015) 15(281):73-7. doi:10.1016/j.jneuroim.2015.03.009.
19. Gresa-Arribas N, Ariño H, Martínez-Hernández E, Petit-Pedrol M, Sabater L, Saiz A, et al. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity. PLoS One (2015) 10(3):e0121364. doi:10.1371/journal.pone.0121364.
20. Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med (2012) 366(5):433-42. doi:10.1056/NEJMoa1107096.
21. Faustman DL, Davis M. The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies. J Mol Med (Berl) (2009) 87(12):1173-8. doi:10.1007/s00109-009-0516-6.
22. Meuth SG, Herrmann AM, Simon OJ, Siffrin V, Melzer N, Bittner S, et al. Cytotoxic CD8+ T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death. J Neurosci (2009) 29(49):15397-409. doi:10.1523/JNEUROSCI.4339-09.2009.
23. Lin YC, Winokur P, Blake A, Wu T, Romm E, Bielekova B. Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis. Ann Clin Transl Neurol (2015) 2(5):445-55. doi:10.1002/acn3.181.